Zacks Investment Research downgraded shares of Pharma Mar (NASDAQ:PHMMF) from a buy rating to a hold rating in a research report released on Saturday.

According to Zacks, “Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company’s product pipeline consists of PM1183, plitidepsin, and PM184 which are in clinical trial stage. It operates primarily in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. Pharma Mar SA is headquartered in Madrid, Spain. “

Pharma Mar (NASDAQ PHMMF) traded down 0.5744% during trading on Friday, reaching $4.2753. 1,281 shares of the company’s stock were exchanged. The stock’s 50-day moving average price is $4.44 and its 200-day moving average price is $4.06. The company’s market capitalization is $1.06 billion. Pharma Mar has a 52-week low of $2.22 and a 52-week high of $4.80.

COPYRIGHT VIOLATION WARNING: “Pharma Mar (PHMMF) Lowered to “Hold” at Zacks Investment Research” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at

Receive News & Stock Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related stocks with our FREE daily email newsletter.